# Seer, Inc.: financial statements, quarterly

SEER · Nasdaq · CIK 1726445 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/seer.md) · [Financials](/companies/seer/financials.md) · [Filings](/companies/seer/filings.md) · [Insiders](/companies/seer/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/seer/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.2](/filings/0000950170-24-122343.md) | [4.4 d](/filings/0000950170-25-030878.md) | [3.1](/filings/0000950170-25-070440.md) | [3.1](/filings/0000950170-25-104121.md) | [4.0](/filings/0001193125-25-269727.md) | [4.0 d](/filings/0001193125-26-085481.md) | [4.2](/filings/0001193125-26-221724.md) | [4.1](/filings/0001193125-26-344858.md) | [4.1](/filings/0001193125-25-269727.md) | [4.2 d](/filings/0001193125-26-085481.md) | [2.8](/filings/0001193125-26-221724.md) | [3.1](/filings/0001193125-26-344858.md) |
| Cost of revenue | $m | [2.0](/filings/0000950170-24-122343.md) | [2.4 d](/filings/0000950170-25-030878.md) | [1.7](/filings/0000950170-25-070440.md) | [1.3](/filings/0000950170-25-104121.md) | [2.1](/filings/0001193125-25-269727.md) | [2.0 d](/filings/0001193125-26-085481.md) | [2.1](/filings/0001193125-26-221724.md) | [1.9](/filings/0001193125-26-344858.md) | [2.0](/filings/0001193125-25-269727.md) | [2.0 d](/filings/0001193125-26-085481.md) | [1.8](/filings/0001193125-26-221724.md) | [1.6](/filings/0001193125-26-344858.md) |
| Gross profit | $m | [2.2](/filings/0000950170-24-122343.md) | [2.0 d](/filings/0000950170-25-030878.md) | [1.4](/filings/0000950170-25-070440.md) | [1.7](/filings/0000950170-25-104121.md) | [1.9](/filings/0001193125-25-269727.md) | [2.0 d](/filings/0001193125-26-085481.md) | [2.1](/filings/0001193125-26-221724.md) | [2.1](/filings/0001193125-26-344858.md) | [2.1](/filings/0001193125-25-269727.md) | [2.2 d](/filings/0001193125-26-085481.md) | [1.0](/filings/0001193125-26-221724.md) | [1.5](/filings/0001193125-26-344858.md) |
| Research and development | $m | [13.2](/filings/0000950170-24-122343.md) | [11.2 d](/filings/0000950170-25-030878.md) | [12.3](/filings/0000950170-25-070440.md) | [12.7](/filings/0000950170-25-104121.md) | [13.0](/filings/0001193125-25-269727.md) | [12.6 d](/filings/0001193125-26-085481.md) | [11.4](/filings/0001193125-26-221724.md) | [12.0](/filings/0001193125-26-344858.md) | [10.8](/filings/0001193125-25-269727.md) | [9.7 d](/filings/0001193125-26-085481.md) | [8.8](/filings/0001193125-26-221724.md) | [8.2](/filings/0001193125-26-344858.md) |
| Selling, general and administrative | $m | [14.8](/filings/0000950170-24-122343.md) | [13.1 d](/filings/0000950170-25-030878.md) | [14.3](/filings/0000950170-25-070440.md) | [16.1](/filings/0000950170-25-104121.md) | [13.3](/filings/0001193125-25-269727.md) | [12.9 d](/filings/0001193125-26-085481.md) | [11.4](/filings/0001193125-26-221724.md) | [10.7](/filings/0001193125-26-344858.md) | [10.7](/filings/0001193125-25-269727.md) | [9.8 d](/filings/0001193125-26-085481.md) | [9.4](/filings/0001193125-26-221724.md) | [10.1](/filings/0001193125-26-344858.md) |
| Operating income | $m | [(25.8)](/filings/0000950170-24-122343.md) | [(22.2) d](/filings/0000950170-25-030878.md) | [(25.2)](/filings/0000950170-25-070440.md) | [(27.1)](/filings/0000950170-25-104121.md) | [(24.3)](/filings/0001193125-25-269727.md) | [(23.5) d](/filings/0001193125-26-085481.md) | [(20.7)](/filings/0001193125-26-221724.md) | [(20.5)](/filings/0001193125-26-344858.md) | [(19.3)](/filings/0001193125-25-269727.md) | [(17.4) d](/filings/0001193125-26-085481.md) | [(17.3)](/filings/0001193125-26-221724.md) | [(16.8)](/filings/0001193125-26-344858.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-070440.md) | [0.0](/filings/0000950170-25-104121.md) | [0.0](/filings/0001193125-25-269727.md) | [0.1 d](/filings/0001193125-26-085481.md) | [0.1](/filings/0001193125-26-221724.md) | [0.0](/filings/0001193125-26-344858.md) | [0.0](/filings/0001193125-25-269727.md) | [0.0 d](/filings/0001193125-26-085481.md) | [0.0](/filings/0001193125-26-221724.md) | [0.0](/filings/0001193125-26-344858.md) |
| Net income | $m | [(21.1)](/filings/0000950170-24-122343.md) | [(17.8) d](/filings/0000950170-25-030878.md) | [(20.7)](/filings/0001193125-25-269727.md) | [(22.9)](/filings/0001193125-25-269727.md) | [(21.3)](/filings/0001193125-25-269727.md) | [(21.7) d](/filings/0001193125-26-085481.md) | [(19.9)](/filings/0001193125-26-344858.md) | [(19.4)](/filings/0001193125-26-344858.md) | [(18.2)](/filings/0001193125-25-269727.md) | [(16.0) d](/filings/0001193125-26-085481.md) | [(16.8)](/filings/0001193125-26-344858.md) | [(16.9)](/filings/0001193125-26-344858.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0000950170-24-122343.md) | not reported | [(0.32)](/filings/0000950170-24-055806.md) | [(0.35)](/filings/0000950170-24-094074.md) | [(0.35)](/filings/0000950170-24-122343.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.33)](/filings/0000950170-24-122343.md) | not reported | [(0.32)](/filings/0000950170-24-055806.md) | [(0.35)](/filings/0000950170-24-094074.md) | [(0.35)](/filings/0000950170-24-122343.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.4](/filings/0000950170-24-122343.md) | [32.5](/filings/0000950170-25-030878.md) | [54.4](/filings/0000950170-25-070440.md) | [31.9](/filings/0000950170-25-104121.md) | [37.6](/filings/0001193125-25-269727.md) | [40.8](/filings/0001193125-26-085481.md) | [52.4](/filings/0001193125-26-221724.md) | [37.9](/filings/0001193125-26-344858.md) | [45.0](/filings/0001193125-25-269727.md) | [47.3](/filings/0001193125-26-344858.md) | [47.3](/filings/0001193125-26-221724.md) | [26.1](/filings/0001193125-26-344858.md) |
| Current assets | $m | [346](/filings/0001628280-23-037381.md) | [331](/filings/0000950170-25-030878.md) | [324](/filings/0000950170-24-055806.md) | [300](/filings/0000950170-24-094074.md) | [264](/filings/0000950170-24-122343.md) | [253](/filings/0001193125-26-085481.md) | [255](/filings/0000950170-25-070440.md) | [226](/filings/0000950170-25-104121.md) | [214](/filings/0001193125-25-269727.md) | [202](/filings/0001193125-26-344858.md) | [182](/filings/0001193125-26-221724.md) | [166](/filings/0001193125-26-344858.md) |
| Total assets | $m | [445](/filings/0001628280-23-037381.md) | [436](/filings/0000950170-25-030878.md) | [422](/filings/0000950170-24-055806.md) | [407](/filings/0000950170-24-094074.md) | [383](/filings/0000950170-24-122343.md) | [367](/filings/0001193125-26-085481.md) | [347](/filings/0000950170-25-070440.md) | [322](/filings/0000950170-25-104121.md) | [309](/filings/0001193125-25-269727.md) | [296](/filings/0001193125-26-344858.md) | [272](/filings/0001193125-26-221724.md) | [257](/filings/0001193125-26-344858.md) |
| Current liabilities | $m | [12.5](/filings/0001628280-23-037381.md) | [13.2](/filings/0000950170-25-030878.md) | [12.8](/filings/0000950170-24-055806.md) | [17.0](/filings/0000950170-24-094074.md) | [14.4](/filings/0000950170-24-122343.md) | [15.3](/filings/0001193125-26-085481.md) | [13.2](/filings/0000950170-25-070440.md) | [11.8](/filings/0000950170-25-104121.md) | [15.0](/filings/0001193125-25-269727.md) | [15.7](/filings/0001193125-26-344858.md) | [10.2](/filings/0001193125-26-221724.md) | [11.3](/filings/0001193125-26-344858.md) |
| Total liabilities | $m | [39.2](/filings/0001628280-23-037381.md) | [39.4](/filings/0000950170-25-030878.md) | [38.4](/filings/0000950170-24-055806.md) | [41.9](/filings/0000950170-24-094074.md) | [38.7](/filings/0000950170-24-122343.md) | [39.0](/filings/0001193125-26-085481.md) | [36.3](/filings/0000950170-25-070440.md) | [34.2](/filings/0000950170-25-104121.md) | [36.8](/filings/0001193125-25-269727.md) | [36.8](/filings/0001193125-26-344858.md) | [30.7](/filings/0001193125-26-221724.md) | [31.0](/filings/0001193125-26-344858.md) |
| Shareholders' equity | $m | [406](/filings/0000950170-24-122343.md) | [397](/filings/0001193125-26-085481.md) | [384](/filings/0001193125-25-269727.md) | [365](/filings/0001193125-25-269727.md) | [345](/filings/0001193125-25-269727.md) | [328](/filings/0001193125-26-344858.md) | [311](/filings/0001193125-26-344858.md) | [288](/filings/0001193125-26-344858.md) | [272](/filings/0001193125-25-269727.md) | [259](/filings/0001193125-26-344858.md) | [241](/filings/0001193125-26-344858.md) | [226](/filings/0001193125-26-344858.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.4) d](/filings/0000950170-24-122343.md) | [(10.2) d](/filings/0000950170-25-030878.md) | [(10.5)](/filings/0000950170-25-070440.md) | [(10.1) d](/filings/0000950170-25-104121.md) | [(14.1) d](/filings/0001193125-25-269727.md) | [(11.5) d](/filings/0001193125-26-085481.md) | [(11.4)](/filings/0001193125-26-221724.md) | [(14.7) d](/filings/0001193125-26-344858.md) | [(7.6) d](/filings/0001193125-25-269727.md) | [(10.8) d](/filings/0001193125-26-085481.md) | [(15.4)](/filings/0001193125-26-221724.md) | [(9.6) d](/filings/0001193125-26-344858.md) |
| Capital expenditure | $m | [4.2 d](/filings/0000950170-24-122343.md) | [1.8 d](/filings/0000950170-25-030878.md) | [0.8](/filings/0000950170-25-070440.md) | [1.2 d](/filings/0000950170-25-104121.md) | [2.2 d](/filings/0001193125-25-269727.md) | [(0.5) d](/filings/0001193125-26-085481.md) | [0.7](/filings/0001193125-26-221724.md) | [0.6 d](/filings/0001193125-26-344858.md) | [0.3 d](/filings/0001193125-25-269727.md) | [0.3 d](/filings/0001193125-26-085481.md) | [0.3](/filings/0001193125-26-221724.md) | [0.0 d](/filings/0001193125-26-344858.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-122343.md) | [0.0 d](/filings/0000950170-25-030878.md) | not reported | not reported | [(3.7) d](/filings/0000950170-24-122343.md) | [0.0 d](/filings/0000950170-25-030878.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.9](/filings/0001628280-22-013102.md) | [60.8](/filings/0001628280-22-021988.md) | [61.1](/filings/0001628280-22-028941.md) | [62.0](/filings/0001628280-23-016850.md) | [62.4](/filings/0001628280-23-028214.md) | [62.5](/filings/0001628280-23-037381.md) | [63.5](/filings/0000950170-24-055806.md) | [63.8](/filings/0000950170-24-094074.md) | [63.9](/filings/0000950170-24-122343.md) | [64.6](/filings/0000950170-24-055806.md) | [64.6](/filings/0000950170-24-094074.md) | [61.2](/filings/0000950170-24-122343.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,372,015 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344858.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.